30095-56-8

Basic information

• Product Name: 3'-Acetamido-2-bromoacetophenone
• Synonyms: 3'-Acetamido-2-bromoacetophenone;2-Bromo-3'-Acetaminoacetophenone;3-ACETHAMINE-A-BROMO-ACETOPHENONE;3-Acetamide-2-bromoacetophenone
• CAS NO: 30095-56-8
• Molecular Formula: C₁₀H₁₀BrNO₂
• Molecular Weight: 256.0959
• Mol File: 30095-56-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 424.781 °C at 760 mmHg
• Flash Point: 210.7 °C
• Appearance: /
• Density: 1.531 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.614
• PKA: 14.62±0.70(Predicted)
• CAS DataBase Reference: 3'-Acetamido-2-bromoacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-Acetamido-2-bromoacetophenone(30095-56-8)
• EPA Substance Registry System: 3'-Acetamido-2-bromoacetophenone(30095-56-8)

Safety Data

• Hazardous Substances Data: 30095-56-8(Hazardous Substances Data)

Usage

General Description

3'-Acetamido-2-bromoacetophenone is a chemical compound with the molecular formula C10H10BrNO2. It is a derivative of acetophenone and contains both an acetamido and a bromo functional group. 3'-Acetamido-2-bromoacetophenone is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds due to its versatile reactivity. It is also used as a reagent in organic reactions, such as the synthesis of heterocyclic compounds and as a building block in the production of complex organic molecules. Additionally, 3'-Acetamido-2-bromoacetophenone has potential applications in the development of new materials and as a research tool in chemical and pharmaceutical research. However, due to its potential health hazards, it should be handled with care and in accordance with proper safety protocols in a controlled laboratory setting.

InChI:InChI=1/C10H10BrNO2/c1-7(13)12-9-4-2-3-8(5-9)10(14)6-11/h2-5H,6H2,1H3,(H,12,13)

Upstream product

• 57946-55-1 1-(3-aminophenyl)-2-bromoethanone 
• 64-19-7 acetic acid 
• 7463-31-2 3-Acetamidoacetophenone 
• 591-19-5 m-Bromoaniline 

Downstream Products

• 103740-34-7 4-(3-aminophenyl)thiazole-2-amine 
• 372096-48-5 [234a] 2-Amino-4-(3-tert-butoxycarbonylaminophenyl)thiazole 
• 37143-09-2 3'-(2,3,5,6-Tetrahydroimidazo[2,1-b]thiazol-6-yl)-acetanilide 
• 37142-98-6 d-6-(m-aminophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole dihydrochloride 

Relevant articles and documents

Synthesis and anticancer activity of novel 2-alkylthio-4-amino-5-(thiazol-2-YL)pyrimidines

A series of new fist-time synthesized of thiazolyl-substituted 4-aminopyrimidine was obtained on the basis of a two-stage process including thioamidation of 4-amino-5-cyanopyrimide followed by one-pot acylation and Hantzsch synthesis in good yield (52–77%

Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents

The emergence of antibiotic resistant pathogens is an ongoing main problem in the therapy of bacterial infections. In order to develop promising antitubercular and antibacterial lead compounds, we designed and synthesized a new series of derivatives of 2-aminothiazole conjugated nitrofuran with activities against both Mycobacterium tuberculosis and Staphylococcus aureus. Eight compounds 12e, 12k, 12l, 12m, 18a, 18d, 18e, and 18j emerged as promising antitubercular agents. Structure–activity relationships (SARs) were discussed and showed that the derivatives substituted at the position-3 of benzene of 5-nitro-N-(4-phenylthiazol-2-yl)furan-2-carboxamide exhibited superior potency. The most potent compound 18e, substituted with benzamide at this position, displayed minimum inhibitory concentrations (MICs) of 0.27 μg/mL against Mtb H37Ra and 1.36 μg/mL against S. aureus. Furthermore, compound 18e had no obvious cytotoxicity to normal Vero cells (IC50= 50.2 μM). The results suggest that the novel scaffolds of aminothiazole conjugated nitrofuran would be a promising class of potent antitubercular and antimicrobial agents.

Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain

Recognizing acetyllysine of histone is a vital process of epigenetic regulation that is mediated by a protein module called bromodomain. To contribute novel scaffolds for developing into bromodomain inhibitors, we utilize a fragment-based drug discovery approach. By successively applying docking and X-ray crystallography, we were able to identify 9 fragment hits from diffracting more than 60 crystals. In the present work, we described four of them and carried out the integrated lead optimization for fragment 8, which bears a 2-thiazolidinone core. After several rounds of structure guided modifications, we assessed the druggability of 2-thiazolidinone by modulating in vitro pharmacokinetic studies and cellular activity assay. The results showed that two potent compounds of 2-thiazolidinones have good metabolic stability. Also, the cellular assay confirmed the activities of 2-thiazolidinones. Together, we hope the identified 2-thiazolidinone chemotype and other fragment hits described herein can stimulate researchers to develop more diversified bromodomain inhibitors.